Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry.
about
An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers.Retinal Electrophysiology Is a Viable Preclinical Biomarker for Drug Penetrance into the Central Nervous System.Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers.Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosisEvaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteersEffect of CYP3A4∗1G and CYP3A5∗3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects.Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers.A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects.Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment.Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.Simultaneous Determination of Twenty-Five Compounds in Rat Plasma Using Ultra-High Performance Liquid Chromatography-Polarity Switching Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study.Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.Is the bioanalytical community ready to revise the use of certain validation concepts and nomenclature?Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.Incurred sample reanalysis: dilemma in its applicability - should it be practiced for all bioanalytical assays involving single (parent or metabolite) or multiple analytes (parent/metabolite or parent with co-administered drugs)?A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers.Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers.Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452Metabolism of ticagrelor in patients with acute coronary syndromes
P2860
Q34998679-338F892F-99A8-4FD0-AE6C-4571E0FFC8F0Q36889744-3516E5BC-FFC8-4817-B7C0-C4B02ECCE059Q37077147-EF59E717-8D16-4209-81BE-A2AD80A348F4Q37225795-2BC4A321-08D6-4643-BC57-4C2C24098898Q37259725-0A67C803-8873-41F3-B0BB-FF8E848B1EABQ37730915-30489A4C-90F9-43E7-93D8-E521A72DC263Q38404995-4B45D834-0AAB-4400-B7E4-D0374E1D5A3FQ38479485-1F277DE3-56A6-4CF6-B759-EA59E67C0E32Q38818086-22B911C2-C6C4-4622-ABC1-28D013C2B8CEQ39478831-9DCF95B5-1BCE-4DFC-8902-21DDC6CE5C89Q39989728-DE1D8B9D-C8E1-411C-BE02-21C9B6359759Q42023858-A400BF07-8505-44DF-9767-27AF57B2A3F1Q42694846-DA60CBF9-D0B2-4206-870A-2A8D8A08B6B7Q43449319-5A7B2E90-8A2A-465C-8B47-B41DF92D8AE6Q45365025-C4A30098-7D48-46D2-B81D-289383BC5C03Q47731076-F5931420-6C04-44AC-807E-F5C8B1A90634Q48102886-FD83C0C4-1EBB-4FA3-8031-142C93D874E6Q48235186-2937612B-3AF7-4F48-A024-ADA821BCC0BFQ48332605-37C8C576-66BE-4706-B321-C174C590F9EDQ48633560-30C5C830-3993-43DC-99F3-63CEE314A4E3Q50468521-A893DF42-D94B-4AA7-B51A-D14C655F4CDBQ50634951-EEBEBD0E-89BC-429C-8B16-DBF652E6BD66Q50924621-3564CA0B-BE82-4493-8F11-DC989DDB47AEQ50986493-3CC43F2F-848A-448A-B636-464449FEAE19Q51367258-BC923A8A-9E44-4E86-93D4-8E89E4C2F733Q57174610-AF0E3507-79FB-48F8-BAD7-F1D201F16A08Q58799733-1133C5FE-ECC4-48CC-8E92-A3FE90BFA98D
P2860
Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Determination of ticagrelor an ...... ography and mass spectrometry.
@ast
Determination of ticagrelor an ...... ography and mass spectrometry.
@en
type
label
Determination of ticagrelor an ...... ography and mass spectrometry.
@ast
Determination of ticagrelor an ...... ography and mass spectrometry.
@en
prefLabel
Determination of ticagrelor an ...... ography and mass spectrometry.
@ast
Determination of ticagrelor an ...... ography and mass spectrometry.
@en
P2093
P1476
Determination of ticagrelor an ...... ography and mass spectrometry.
@en
P2093
Henrik Sillén
Melanie Cook
Patty Davis
P304
P356
10.1016/J.JCHROMB.2010.06.018
P577
2010-06-25T00:00:00Z